Charles-Hugo M.
- Country
- France
- Department
- Department of pneumology, thoracic oncology and intensive respiratory care
Research Overview
- A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Admilparant in Participants with Progressive Pulmonary Fibrosis
- Efficacy and Safety of Early Depemokimab Initiation as Add-on Therapy in Patients with Chronic Obstructive Pulmonary Disease and Type 2 Inflammation
- Randomized Trial of Early Pleural Irrigation with Sodium Chloride Versus Standard Care for Complicated Pleural Infections
Data & Insights
Has run more than one trial at 114 of 311 partner sites.
Specializations
Pulmonary Fibrosis Research
Specializes in investigating therapeutic approaches for idiopathic pulmonary fibrosis, with particular focus on progressive disease management and innovative treatment combinations.
- Disease progression management
- Combination therapy assessment
- Lung function evaluation
Explores novel therapeutic agents and their effects on respiratory function in IPF patients.
Interstitial Lung Disease Studies
Conducts research in interstitial lung diseases, including investigations of inflammatory components and systemic sclerosis-associated ILD.
- Inflammatory pathway modulation
- Progressive ILD treatment
- Autoimmune-related lung conditions
Investigates targeted therapies for various forms of ILD with focus on inflammatory mechanisms.
Advanced Respiratory Medicine
Focuses on treatment strategies for chronic obstructive pulmonary disease and advanced lung cancer, particularly EGFR-mutated variants.
- COPD exacerbation management
- Targeted lung cancer therapy
- Novel therapeutic approaches
Examines innovative treatments for complex respiratory conditions and their clinical outcomes.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.